Abstract Search

ba0003OP1 | Clinical | ECTS2014

A transdermal patch delivering the PTHrP_1--34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Yates John , Alexandersen Peter , Krogsaa Annesofie , Nedergaard Bettina , Clarkin Marcie , Hattersley Gary , Hansen Kris , Karsdal Morten , Christiansen Claus

see PP351....

0 shares

ba0003pp351 | Osteoporosis: treatment | ECTS2014

A transdermal patch delivering the PTHrP_1–34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Yates John , Alexandersen Peter , Krogsaa Annesofie , Nedergaard Bettina , Clarkin Marcie , Hattersley Gary , Hansen Kris , Karsdal Morten , Christiansen Claus

Abaloparatide (BA058) is a synthetic analog of PTHrP134 which greatly increases bone mass and bone strength with preservation of normal bone quality in animal models of osteoporosis. Daily s.c. abaloparatide (ABLSC) at doses of up to 80 μg daily in postmenopausal women with osteoporosis for up to 48 weeks were associated with increases in spine and femoral neck BMD of up to 12.9 and 4.1% respectively and good safety and tolerability. The increa...

1 shares

ba0001pp450 | Osteoporosis: treatment | ECTS2013

Transdermal delivery of BA058, a novel analog of hPTHrP (1-34), with a short wear time patch in preclinical and clinical studies

Hattersley Gary , Hansen Kris , Determan Amy , Brown Ken , Mckay Kate , Guerriero Jonathan , McCarthy Dan , Lyttle C Richard , St L O'Dea Louis

BA058 is being developed as an anabolic therapy for the treatment of osteoporosis. Daily BA058 SC injection has produced promising safety and efficacy results in early clinical studies, and is currently enrolling in a Phase 3 fracture prevention study. There is, however, a significant need for an alternative to injection that improves patient convenience and compliance. We have investigated the use of a solid Microstructured Transdermal System (3M) for transdermal (TD) deliver...

0 shares

Bone Abstracts

A transdermal patch delivering the PTHrP_1--34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

A transdermal patch delivering the PTHrP_1–34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Transdermal delivery of BA058, a novel analog of hPTHrP (1-34), with a short wear time patch in preclinical and clinical studies

BiosciAbstracts

Bone Abstracts

A transdermal patch delivering the PTHrP1--34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

A transdermal patch delivering the PTHrP1–34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Transdermal delivery of BA058, a novel analog of hPTHrP (1-34), with a short wear time patch in preclinical and clinical studies

BiosciAbstracts

A transdermal patch delivering the PTHrP_1--34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

A transdermal patch delivering the PTHrP_1–34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo